Title: Continuous renal replacement therapy for inflammation-related anemia, iron metabolism and short-term outcomes in patients with critical acute kidney injury: A single-center observational study

Biography:

Abstract

Background: Continuous renal replacement therapy (CRRT) is frequently used for patients with critical acute kidney injury. However, its effect on inflammation-related anemia, iron metabolism and short-term prognosis remains largely unknown.

Methods: In this single-center retrospective observational study, data from a total of 193 cases of critical acute kidney injury were collected and analyzed. Comparisons were made between those treated with CRRT (CRRT group) and without CRRT (non-CRRT group) at day 3, 7 and 14 after intensive care unit admission. Iron metabolism biomarkers assessed included iron, ferritin, transferrin saturation rate, and soluble transferrin receptor. Short-term prognosis is defined as 28-dya mortality.

Results: Of the 193 cases included, 112 patients (58.03%) received CRRT treatment. The most common causes for acute kidney injury in this study were sepsis (69.43%), followed by ischemia reperfusion injury (18.65%) and nephrotoxicity (6.22%). Compared with the non-CRRT group, patients in the CRRT group were associated with significantly higher sequential organ failure assessment score (P<0.001). Hemoglobin levels between the 2 groups were statistically insignificant at all time points. However, levels of iron, ferritin and transferrin saturation rate in the CRRT group were significantly higher than those in the non-CRRT group at day 14, despite the soluble transferrin receptor level showed no statistical significance. The 28-day mortality rate between the CRRT and non-CRRT group were similar (39.29% vs , 24.69%, P=0.26).

Conclusion: CRRT treatment in patients with critical acute kidney injury improves iron metabolism but has limited effect on inflammation-related anemia and short-term mortality.